AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29270062 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting accrual (including institutional, clinician, and patient factors)
Number of subjects: 0
Study 29270062 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication and education efforts directed at referring physicians
Number of subjects: 0
Study 29270080 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 31
Study 29270208 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone support (daily calls initiated by a breastfeeding support team)
Number of subjects: 365
Study 29270208 — intervention group
Group type: COMPARATOR
Intervention: Reactive telephone support (mothers could call the breastfeeding support team)
Number of subjects: 365
Study 29270312 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention
Number of subjects: 80
Study 29270312 — intervention group
Group type: COMPARATOR
Intervention: Standard services (control)
Number of subjects: 80
Study 29270487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab 1 mg/kg
Number of subjects: 36
Study 29270487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresolimumab 4 mg/kg
Number of subjects: 36
Study 29270487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29270685 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A treatment
Number of subjects: 1036
Study 29270725 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation from a 46-year-old mother to a 23-year-old daughter; surgery duration: 12.12/5.95 hours.
Number of subjects: 3
Study 29270725 — intervention group
Group type: COMPARATOR
Intervention: Uterus transplantation attempt from a 61-year-old donor; surgery duration: 13.10 hours.
Number of subjects: 3
Study 29270725 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation from a 46-year-old mother to a 23-year-old daughter; surgery duration: 9.05/4.52 hours.
Number of subjects: 3
Study 29270781 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg maximum dose)
Number of subjects: 1723
Study 29270781 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 1723
Study 29270787 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT at baseline (PET0), after induction (PET-AI), and end of treatment (PET-EoT)
Number of subjects: 86
Study 29270787 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT scans analyzed using Krippendorff's alpha coefficient
Number of subjects: 86
Study 29270787 — intervention group
Group type: EXPERIMENTAL
Intervention: Deauville score (DS) for positivity thresholds (DS 2, 3, 4, 5)
Number of subjects: 86
Study 29270787 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPeTUs criteria for PET interpretation
Number of subjects: 86
Study 29270788 — intervention group
Group type: EXPERIMENTAL
Intervention: F18-choline PET/CT
Number of subjects: 25
Study 29270788 — intervention group
Group type: EXPERIMENTAL
Intervention: F18-choline PET/CT guided surgery
Number of subjects: 25
Study 29270800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal PVDF mesh enhanced with iron particles (DynaMesh IPOM visible)
Number of subjects: 15
Study 29271373 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1792
Study 29271373 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1792
Study 29271373 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 1792
Study 29271830 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care creatinine assay
Number of subjects: 0
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC0 (circulating tumor cell nonzero at baseline and 0 at 13 weeks)
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC conversion (≥ 5 CTCs at baseline, ≤ 4 at 13 weeks)
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% decrease in CTC count
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% decrease in CTC count
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% decrease in CTC count
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% decrease in PSA level
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% decrease in PSA level
Number of subjects: 6081
Study 29272162 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% decrease in PSA level
Number of subjects: 6081
Study 29272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) dose-escalation cohort, 1.8 mg/kg IV every 3 weeks for two cycles, escalated to 2.4 mg/kg for patients with stable disease or partial response.
Number of subjects: 56
Study 29272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) standard/fixed-dose cohort.
Number of subjects: 56
Study 29272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) as a bridge to autologous hematopoietic cell transplantation (AHCT).
Number of subjects: 56
Study 29272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in CR at the time of AHCT.
Number of subjects: 56
Study 29272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who proceeded to AHCT directly after receiving BV alone.
Number of subjects: 56
Study 29272368 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Electrosurgical Excision Procedure (LEEP)
Number of subjects: 400
Study 29272368 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 400
Study 29272443 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly DHA-PQ (2880 mg PQ)
Number of subjects: 83
Study 29272443 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly DHA-PQ (960 mg PQ)
Number of subjects: 83
Study 29272443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose daily DHA-PQ (320 or 160 mg PQ)
Number of subjects: 83
Study 29272443 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 83
Study 29272443 — intervention group
Group type: EXPERIMENTAL
Intervention: Low daily DHA-PQ dosing
Number of subjects: 83
Study 29272480 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomicroscopic mucosal healing score (eMHs) after 3 anti-TNF applications
Number of subjects: 23
Study 29272480 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 23
Study 29272906 — intervention group
Group type: EXPERIMENTAL
Intervention: Stylet slow-pull technique
Number of subjects: 121
Study 29272906 — intervention group
Group type: COMPARATOR
Intervention: Suction technique
Number of subjects: 121
Study 29273043 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-M questionnaire
Number of subjects: 70
Study 29273043 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-M scores
Number of subjects: 70
Study 29273043 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDs for FACT-M domains
Number of subjects: 70
Study 29273054 — intervention group
Group type: EXPERIMENTAL
Intervention: NG12-1 vasoconstrictor, applied topically, 30 daily treatments before radiotherapy.
Number of subjects: 9
Study 29273054 — intervention group
Group type: COMPARATOR
Intervention: Control area (no treatment).
Number of subjects: 9
Study 29273071 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-22
Number of subjects: 12
Study 29273071 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-486-3p
Number of subjects: 12
Study 29273071 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-382
Number of subjects: 12
Study 29273071 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 29273095 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440
Study 29273095 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 440
Study 29273113 — intervention group
Group type: EXPERIMENTAL
Intervention: Social empowerment program (Creating Opportunities through Mentoring, Parental Involvement and Safe Spaces) with 40 fixed-curriculum, mentor-facilitated sessions once a week for 10 months and 10 caregiver discussion sessions once a month for the same period
Number of subjects: 919
Study 29273113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to the curriculum)
Number of subjects: 919
Study 29273410 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200mg intravenously every 3 weeks until loss of clinical benefit
Number of subjects: 315
Study 29273636 — intervention group
Group type: EXPERIMENTAL
Intervention: Young patients with ACS (aged ≤45 years)
Number of subjects: 1182
Study 29273636 — intervention group
Group type: COMPARATOR
Intervention: Older patients with ACS (aged >45 years)
Number of subjects: 1182
Study 29273636 — intervention group
Group type: EXPERIMENTAL
Intervention: Men aged ≤45 years with ACS
Number of subjects: 1182
Study 29273636 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged ≤45 years with ACS
Number of subjects: 1182
Study 29273636 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger women with ACS compared to younger men
Number of subjects: 1182
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer incidence rates among females
Number of subjects: 15840
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer incidence rates among males
Number of subjects: 15840
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cancer diagnoses among females
Number of subjects: 15840
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cancer diagnoses among males
Number of subjects: 15840
Study 29273649 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ASIR between genders
Number of subjects: 15840
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Common cancer types in children and adolescents
Number of subjects: 15840
Study 29273649 — intervention group
Group type: EXPERIMENTAL
Intervention: Leading cancer types in adults
Number of subjects: 15840
Study 29273652 — intervention group
Group type: EXPERIMENTAL
Intervention: GARFIELD-AF risk tool
Number of subjects: 39898
Study 29273652 — intervention group
Group type: COMPARATOR
Intervention: CHA
Number of subjects: 39898
Study 29274015 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring device and behavioral feedback
Number of subjects: 0
Study 29274015 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29274193 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 6 weeks
Number of subjects: 68
Study 29274193 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg once daily for 8 weeks
Number of subjects: 68
Study 29274193 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported in 63.2% of patients (43/68), mainly grade 1/2, none led to treatment discontinuation.
Number of subjects: 68
Study 29274733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT)
Number of subjects: 70
Study 29274733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 29275146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, levofloxacin, or fosfomycin (antibiotic prophylaxis)
Number of subjects: 294
Study 29275146 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS-Bx procedure
Number of subjects: 294
Study 29275146 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 294
Study 29275778 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus nutrition psychoeducation (MINP)
Number of subjects: 31
Study 29275778 — intervention group
Group type: COMPARATOR
Intervention: Nutrition psychoeducation (NP)
Number of subjects: 31
Study 29275778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 31
Study 29275821 — intervention group
Group type: EXPERIMENTAL
Intervention: Eunice Kennedy Shriver National Institute of Child Health and Human Development Study
Number of subjects: 0
Study 29275821 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERGROWTH
Number of subjects: 0
Study 29275821 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization Multicentre Growth Reference Study
Number of subjects: 0
Study 29275855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low epIQ subgroup (epIQ <90)
Number of subjects: 292
Study 29275926 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal PEEP level during the first course of mechanical ventilation
Number of subjects: 278
Study 29275926 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in PEEP levels between neonatal centers
Number of subjects: 278
Study 29275946 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined ECG abnormalities (including nonsinus rhythm, multiple premature ventricular conductions, short PR interval, first-degree atrioventricular block, complete left bundle branch block, Q wave/T wave/ST-segment abnormalities)
Number of subjects: 3416
Study 29275946 — intervention group
Group type: EXPERIMENTAL
Intervention: Any ECG abnormality
Number of subjects: 3416
Study 29275946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of specific ECG abnormalities
Number of subjects: 3416
Study 29276022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg or 1.8 mg/kg) plus bendamustine (70 mg/m2)
Number of subjects: 65
Study 29276022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) plus bendamustine (80 mg/m2)
Number of subjects: 65
Study 29276625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of atrial appendage micrografts in a fibrin gel covered with a tissue-engineered ECM sheet
Number of subjects: 6
Study 29276625 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial transplantation of atrial appendage micrografts
Number of subjects: 6
Study 29276625 — intervention group
Group type: COMPARATOR
Intervention: Routine CABG surgery (control group)
Number of subjects: 6
Study 29276860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding
Number of subjects: 0
Study 29276860 — intervention group
Group type: COMPARATOR
Intervention: Standard, high-carbohydrate, high-fat, high-protein, low-protein diets
Number of subjects: 0
Study 29277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia therapy with aerobic exercise via bicycle ergometer (n = 5)
Number of subjects: 7
Study 29277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphasia therapy with stretching (n = 2)
Number of subjects: 7
Study 29277374 — intervention group
Group type: COMPARATOR
Intervention: Aphasia therapy alone (Block 1)
Number of subjects: 7
Study 29277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 4 participants)
Number of subjects: 7
Study 29277374 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (n = 1 participant)
Number of subjects: 7
Study 29278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission/Low Disease Activity (LDA) at Week 24
Number of subjects: 0
Study 29278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 0
Study 29278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Disease Activity (LDA)
Number of subjects: 0
Study 29278006 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission/LDA
Number of subjects: 0
Study 29278006 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29279281 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 0.5 mL PCV13 in previously vaccinated subjects (n=284)
Number of subjects: 883
Study 29279281 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of 0.5 mL PCV13 in previously vaccinated subjects (n=288)
Number of subjects: 883
Study 29279305 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Cerebellar Functional Severity (CCFS) Scale
Number of subjects: 383
Study 29279305 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 383
Study 29279305 — intervention group
Group type: COMPARATOR
Intervention: CCFS and SARA scales
Number of subjects: 383
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% protein diet
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% protein diet
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% protein diet
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat and protein
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in fat mass and weight
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fat cell size (FCS)
Number of subjects: 23
Study 29280309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between glucose disposal and FCS
Number of subjects: 23
Study 29280355 — intervention group
Group type: EXPERIMENTAL
Intervention: 50, 125, 300, or 600 mg of testosterone enanthate weekly injections
Number of subjects: 0
Study 29280355 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg dutasteride daily
Number of subjects: 0
Study 29280355 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 0
Study 29280716 — intervention group
Group type: EXPERIMENTAL
Intervention: Test of Sensory Functions in Infants
Number of subjects: 60
Study 29280762 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin at 1.2 mg/kg with AVD (doxorubicin, vinblastine, dacarbazine)
Number of subjects: 6
Study 29280921 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified definition of non-alcoholic steato-hepatitis (NASH) that does not require the presence of steatosis and the presence of both lobular inflammation and ballooning
Number of subjects: 1081
Study 29280921 — intervention group
Group type: COMPARATOR
Intervention: Standard definitions of NASH
Number of subjects: 1081
Study 29281086 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet (AP) monotherapy
Number of subjects: 51270
Study 29281086 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant (AC) monotherapy
Number of subjects: 51270
Study 29281086 — intervention group
Group type: EXPERIMENTAL
Intervention: AP monotherapy
Number of subjects: 51270
Study 29281086 — intervention group
Group type: COMPARATOR
Intervention: AC monotherapy
Number of subjects: 51270
Study 29281086 — intervention group
Group type: EXPERIMENTAL
Intervention: AP + AC and no antithrombotic therapy
Number of subjects: 51270
Study 29281579 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examinations at 1.5 Tesla
Number of subjects: 1509
Study 29282024 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation individual therapy (ERITA) for 12 weeks
Number of subjects: 17
Study 29282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid
Number of subjects: 300
Study 29282032 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 300
Study 29282054 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational program (EDU; n=112)
Number of subjects: 239
Study 29282054 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n=127)
Number of subjects: 239
Study 29282090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5.0 mg BID for Cohort 1, 2.5 mg BID for Cohort 2, 3.0 mg BID for Cohort 3)
Number of subjects: 26
Study 29282090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral solution, grape flavor)
Number of subjects: 26
Study 29282090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (multiple-dose, twice daily for 5 days)
Number of subjects: 26
Study 29282099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for six months
Number of subjects: 0
Study 29282099 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for six months
Number of subjects: 0
Study 29282109 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient training intervention for healthcare workers (HCWs)
Number of subjects: 240
Study 29282154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-paid material incentive (iPad mini 2) with in-person recruitment and intervention plus virtual simulation
Number of subjects: 989
Study 29282154 — intervention group
Group type: COMPARATOR
Intervention: Monetary reward ($100 gift card) conditional on completion with email recruitment and vignette-based questionnaire
Number of subjects: 989
Study 29282263 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D ultrasound shear wave elastography (SWE) in fetuses of women with TPL requiring corticosteroids
Number of subjects: 2
Study 29282263 — intervention group
Group type: COMPARATOR
Intervention: 2-D ultrasound shear wave elastography (SWE) in fetuses of women with uncomplicated pregnancies
Number of subjects: 2
Study 29282271 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumour cells (CTCs) detection in peripheral blood samples during yearly screening rounds for 3 years plus a 1-year follow-up.
Number of subjects: 600
Study 29282271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) during yearly screening rounds for 3 years plus a 1-year follow-up.
Number of subjects: 600
Study 29282329 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA levels in CSF from prodromal HD participants
Number of subjects: 60
Study 29282329 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 29282329 — intervention group
Group type: COMPARATOR
Intervention: Diagnosed HD participants
Number of subjects: 60
Study 29282548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution peripheral quantitative computerized tomography (HRpQCT)
Number of subjects: 1575
Study 29282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip QCT
Number of subjects: 1575
Study 29282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcaneus texture analysis
Number of subjects: 1575
Study 29282548 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers
Number of subjects: 1575